Data and safety monitoring committees in clinical trials
著者
書誌事項
Data and safety monitoring committees in clinical trials
(Chapman & Hall/CRC biostatistics series, 30)
Chapman & Hall/CRC, c2009
大学図書館所蔵 全3件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes bibliographical references (p. 155-166) and index
内容説明・目次
内容説明
Focusing on the practical clinical and statistical issues that arise in pharmaceutical industry trials, this book summarizes the author's experience in serving on many data monitoring committees (DMCs) and in heading up a contract research organization that provided statistical support to nearly seventy-five DMCs. It explains the difference in DMC operations between the pharmaceutical industry and National Institutes of Health (NIH)-sponsored trials. Leading you through the types of reports for adverse events and lab values, the author presents the statistical requirements of data monitoring committees and gives advice on how statisticians can best interact with physician members of these committees. He also shows how physicians think differently about safety data than statisticians, proving that both views are needed.
目次
Introduction
What Is a Data Monitoring Committee (DMC)?
Some Definitions
DMC in Federal Government-Sponsored Clinical Trials versus Pharmaceutical Industry Clinical Trials
Stewardship
Some Recent History
DMC's Place in the Drug Development Cycle6
Pharmaceutical Industry Demographics
Conclusion
DMCounselor
Organization of a Safety Monitoring Program for a Confirmatory Trial
Members of the Safety Monitoring Team
How Is a DMC Created?
Membership
Term
Conflicts of Interest
Compensation
Liability and Indemnification
Sponsor DMC Relationship
Interdisciplinary Training .
Conclusion
DMCounselor
Meetings
DMC Charter
Types of Meetings
Orientation Meeting
Data ReviewMeetings
Ad Hoc Meetings
Conclusion
DMCounselor
Clinical Issues
Goals of Safety Analysis .
Definitions
Safety Data
Deaths .
Impact of Multinational Trials
Conclusion
DMCounselor
Statistical Issues
Goals of Statistical Analysis
Useful Data Displays
Analysis Methods-Frequentist
Power
Multiplicity
Analysis Methods-Likelihood
Analysis Methods-Bayesian.
Conclusion
DMCounselor
Bias and Pitfalls
What Is Bias?
Sources of Bias.
Knowledge of Treatment Assignment
Reporting Bias
Competing Risks
Conclusion
DMCounselor
Data Monitoring Committee Decisions.1
Types of DMC Decisions 1
Decision-Making Environment .2
Risk versus Benefit Analyses2
When a Safety Issue Arises.3
Information beyond the Present Trial.8
Meta-Analysis0
Final Meeting2
Special Problems with Infant Pharma Companies2
Conclusion3
DMCounselor .3
Emerging Issues9
Introduction.9
Issues in Technology.0
Issues Due to Maturing of DMC Processes and Evolution of the Pharmaceutical Industry
Resignation from a DMC.0
Conclusion0
DMCounselor .1
Appendix5
Glossary1
List of Abbreviations3
References 5
Index7
「Nielsen BookData」 より